【財華社訊】東曜藥業-B(01875.HK)公佈，截至2024年9月30日止九個月，營業收入約8.09億元(人民幣,下同)，同比增長49%，主要是由於自研產品銷售及CDMO/CMO業務的穩步增長。淨利潤3540.3萬元，上年同期為虧損3239.1萬元。
- Headlines
- 東曜藥業-B(01875.HK)前三季度扭虧為盈淨利潤3540.3萬元
東曜藥業-B(01875.HK)前三季度扭虧為盈淨利潤3540.3萬元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.